Your browser is no longer supported. Please, upgrade your browser.
Settings
MRK Merck & Co. Inc. daily Stock Chart
MRK [NYSE]
Merck & Co. Inc.
IndexDJIA S&P500 P/E15.20 EPS (ttm)3.85 Insider Own0.04% Shs Outstand2.83B Perf Week0.77%
Market Cap165.33B Forward P/E15.35 EPS next Y3.81 Insider Trans-30.83% Shs Float2.82B Perf Month2.79%
Income11.17B PEG2.64 EPS next Q0.81 Inst Own75.60% Short Float1.16% Perf Quarter-1.00%
Sales41.40B P/S3.99 EPS this Y176.90% Inst Trans0.63% Short Ratio3.45 Perf Half Y-4.26%
Book/sh16.85 P/B3.47 EPS next Y10.59% ROA11.00% Target Price65.47 Perf Year3.87%
Cash/sh5.52 P/C10.60 EPS next 5Y5.75% ROE23.50% 52W Range51.29 - 62.63 Perf YTD4.67%
Dividend1.80 P/FCF126.40 EPS past 5Y-6.30% ROI0.50% 52W High-6.57% Beta0.43
Dividend %3.08% Quick Ratio1.30 Sales past 5Y9.00% Gross Margin61.40% 52W Low14.10% ATR0.84
Employees70000 Current Ratio1.60 Sales Q/Q-8.20% Oper. Margin37.70% RSI (14)52.32 Volatility1.73% 1.36%
OptionableYes Debt/Eq0.63 EPS Q/Q-42.10% Profit Margin27.00% Rel Volume0.74 Prev Close58.54
ShortableYes LT Debt/Eq0.53 EarningsJul 28 BMO Payout45.30% Avg Volume9.48M Price58.52
Recom2.50 SMA200.92% SMA500.14% SMA2000.85% Volume6,976,991 Change-0.03%
Jun-17-15Initiated Piper Jaffray Neutral
Apr-29-15Reiterated UBS Buy $64 → $68
Apr-29-15Reiterated Argus Buy $66 → $70
Apr-30-14Reiterated Argus Buy $62 → $66
Apr-11-14Reiterated MKM Partners Buy $64 → $70
Feb-05-14Reiterated Argus Buy $54 → $62
Jan-14-14Reiterated MKM Partners Buy $59 → $64
Jun-03-13Reiterated MKM Partners Buy $54 → $59
Apr-15-13Reiterated Barclays Overweight $45 → $60
Feb-04-13Reiterated MKM Partners Buy $51 → $52
Feb-04-13Reiterated Barclays Overweight $46 → $45
Nov-20-12Upgrade MKM Partners Neutral → Buy $47 → $51
Oct-17-12Reiterated MP Advisors Outperform $45 → $50
Jul-30-12Reiterated UBS Buy $45 → $50
Jul-13-12Upgrade MP Advisors Market Perform → Outperform $45
Feb-03-12Reiterated Barclays Capital Overweight $38 → $40
Feb-03-12Downgrade MKM Partners Buy → Neutral $42 → $40
Nov-29-11Initiated MKM Partners Buy $38
Sep-14-11Reiterated Barclays Capital Overweight $41 → $38
May-16-11Reiterated UBS Buy $40 → $42
Jul-30-15 06:49PM  Amgen, Alexion Top Views, But Their Outlooks Differ
11:12AM  Bayer (BAYRY) Q2 Revenues Up Y/Y, 2015 Guidance Revised - Analyst Blog
09:06AM  Novartiss Shares Fall after 2Q15 Earnings
08:00AM  Celebrity Chef Leticia Moreinos Schwartz, Merck and the American Diabetes Association Challenge Hispanics with Type 2 Diabetes to Get to Their A1C Goal PR Newswire
Jul-29-15 04:01PM  The 4 Stocks That Boosted the DJIA on Wednesday at 24/7 Wall St.
11:06AM  Why Sandoz Revenues Were Important for Novartis in 2Q15
10:10AM  Company News for July 29, 2015 - Corporate Summary
07:00AM  These High-Quality Companies Are on Sale at Morningstar
06:00AM  The Top Drug Launches Of All Time at Forbes
12:07AM  Merck Earnings Hurt by Arthritis Drug Knockoffs at The Wall Street Journal
Jul-28-15 06:52PM  Google, Amazon And Microsoft Curb Spending To Boost Profits
06:47PM  Gilead beats Street 2Q forecasts on surge in sales, profit
05:32PM  Pfizer, Merck Beat Q2 Views; Sanofi Makes PD-1 Deal at Investor's Business Daily
04:51PM  Merck (MRK) Earnings Report: Q2 2015 Conference Call Transcript at TheStreet
04:34PM  Merck Adds Johns Hopkins Dean, Former Accenture CFO to Board at Bloomberg
04:34PM  MERCK & CO., INC. Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles of Inc. or By
04:34PM  Gilead Lifts Sales View As Hep C Drugs Top
04:15PM  Pamela J. Craig and Dr. Paul B. Rothman Elected to Merck Board of Directors Business Wire
03:59PM  Edited Transcript of MRK earnings conference call or presentation 28-Jul-15 12:00pm GMT
01:35PM  Drugmaker Pfizer tops Street 2Q forecasts, raises forecast
01:33PM  Gilead Sciences: How Will the Market React to Slowing U.S. Hep-C Sales? at Barrons.com
12:00PM  Stocks Higher after Multiday Slide
11:46AM  Why Novartiss Revenues Declined Marginally
10:43AM  Merck Tops on Q2 Earnings & Revenues, Revises Outlook - Analyst Blog
10:13AM  Merck tops Street 2Q forecasts despite lower sales, profit
10:03AM  Merck (MRK) Stock Retreating Despite Earnings Beat at TheStreet
09:55AM  Are Merck Earnings Enough?
09:20AM  Merck expanding cancer drug pipeline: CEO
09:03AM  Merck beats Q2 earnings estimates as sales fall at USA TODAY
08:57AM  Pfizer beats, Dupont warns; UPS hurt by dollar; Ford soars
08:54AM  Cramer: Hats off to China
08:43AM  Merck (MRK) Tops on Q2 Earnings & Revenues - Tale of the Tape
08:36AM  Early movers: F, PFE, MRK, DD, WYN, DHI & more at CNBC
08:33AM  Pfizer, Merck 2Q Profits Beat Estimates
08:13AM  Wall Street's bounce back; Yellen in spotlight; Trump's $21M penthouse deal
08:00AM  Merck raises forecast on strong sales of diabetes, cancer drugs
08:00AM  Merck & Co Inc Earnings Call scheduled for 8:00 am ET today
07:56AM  Merck Earnings Top Views Amid Cost Cuts at The Wall Street Journal
07:44AM  Dissecting big pharma's numbers: Pro
07:29AM  Merck beats profit expectations and raises its outlook at MarketWatch
07:22AM  Merck tops Street 2Q forecasts
07:22AM  Merck Second-Quarter Profit Beats Estimates, Target Raised at Bloomberg
07:16AM  Strong dollar weighs on Merck revenue
07:07AM  Q2 2015 Merck & Co Inc Earnings Release - Before Market Open
07:00AM  Merck Announces Second-Quarter 2015 Financial Results Business Wire
06:45AM  Merck Enhances Immuno-Oncology Portfolio with Acquisition of cCAM Biotherapeutics Business Wire
06:31AM  Merck Targets Toughest Cases for Foothold in Hepatitis C Market at Bloomberg
06:30AM  Merck Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Grazoprevir/Elbasvir, an Investigational Therapy for Treatment of Chronic Hepatitis C Genotypes 1, 4 and 6 Infection Business Wire
Jul-27-15 08:15PM  Fed Meeting, Twitter Earnings, Consumer Data in Focus Tuesday at TheStreet
02:52PM  What to Watch in the Day Ahead - Tuesday, July 28 Reuters
02:22PM  Merck & Pfizer earnings expectations
01:40PM  What to Expect from Merck Earnings
01:06PM  Dollar Plagues Pharma Earnings But Did Street Get It Right?
12:19PM  What to Expect When Merck (MRK) Reports Earnings Tomorrow at TheStreet
11:51AM  Pfizer And Merck Earnings Previews: Mega-Cap Pharmas Try To Stem Revenue Erosion at Insider Monkey
11:41AM  Upbeat Reckitt lifts growth forecast on better consumer sentiment at Financial Times
09:02AM  3 Important Questions We Want Answered When Merck Reports Its Q2 Results at Motley Fool
08:30AM  Merck Receives Positive CHMP Opinion for Investigational Antibiotic ZERBAXA (Ceftolozane and Tazobactam) Business Wire
08:21AM  Short Sellers Run For Cover From Major Pharma at 24/7 Wall St.
06:52AM  What to expect from Merck & Pfizer tomorrow
Jul-26-15 12:15PM  [video]What to Watch in the Week Ahead: Twitter, Facebook Earnings, GDP at TheStreet
10:21AM  BioPharma Earnings Bracing for Merck, Pfizer, Amgen, Gilead at 24/7 Wall St.
Jul-24-15 05:57PM  Bristol-Myers wins approval for 1st hepatitis C type 3 drug
04:14PM  MERCK & CO., INC. Files SEC form 8-K, Change in Directors or Principal Officers
03:10PM  Will Merck (MRK) Pull a Surprise this Earnings Season? - Analyst Blog
01:15PM  Video: Steady buying in VIX calls
12:45PM  Countdown to health care earnings
12:06PM  Merck draws puts before earnings
11:00AM  Merck, Baupost join $55M investment in early-stage biotech, RaNA at bizjournals.com
Jul-23-15 03:16PM  Merck's Anti-PD-1 Therapy Melanoma Drug Gets EU Nod - Analyst Blog
01:44PM  FDA Oks Pricey New Cholesterol Drug For Certain Patients at Fox Business
01:04PM  Bristol-Myers Gets a Revenue Boost from Opdivo at The Wall Street Journal
12:47PM  Bristol's Earnings Beat Fails to Impress; Shares Fall 1.9% at Barrons.com
12:15PM  Cancer Drugs Lift Lilly's Outlook at Barrons.com
11:02AM  MSD Announces European Medicines Agency Acceptance of Marketing Authorisation Application for Grazoprevir/Elbasvir, an Investigational Therapy for Treatment of Chronic Hepatitis C Infection Business Wire
11:02AM  Merck Announces European Medicines Agency Acceptance of Marketing Authorization Application for Grazoprevir/Elbasvir, an Investigational Therapy for Treatment of Chronic Hepatitis C Infection Business Wire
07:59AM  Merck Serono and BioMed X Extend Collaboration CNW Group
06:45AM  Short-term put buying hits Merck
12:01AM  Merck Joins $55M Wager on RaNA Therapeutics, Pushing Frontier With RNA Medicines at Forbes
Jul-22-15 07:58PM  Volunteers find it hard to put skills to good use at Financial Times
04:13PM  What's Coming For Large-Cap Pharma Stocks This Earnings Season?
01:28PM  Merck Announces Fourth-Quarter 2015 Dividend Business Wire
07:00AM  European Commission Approves MSDs Anti-PD-1 Therapy, KEYTRUDA┬« (pembrolizumab), for Both First-line and Previously-treated Patients with Advanced Melanoma Business Wire
07:00AM  European Commission Approves Mercks Anti-PD-1 Therapy, KEYTRUDA┬« (pembrolizumab), for Both First-line and Previously-treated Patients with Advanced Melanoma Business Wire
07:00AM  6 Stocks to Watch at Morningstar
01:49AM  Belgium's Ablynx triples cooperation deal with Merck & Co Reuters
Jul-21-15 08:00AM  Merck Marks 30-Year Milestone in Commitment to Innovation and Care in HIV/AIDS Business Wire
Jul-18-15 11:03AM  These 2 Stocks Doubled in 2015 -- Is 1 Still a Buy? at Motley Fool
Jul-17-15 06:27PM  The Long & Short (Term) Of The Pharmaceutical Sector
Jul-15-15 06:36PM  7 Reasons Foreign Stocks May Outperform In 2nd Half at Investor's Business Daily
08:00AM  Gardasil HPV Vaccine Safety Assessed In Most Comprehensive Study To Date at Forbes
08:00AM  Award-Winning Actress S. Epatha Merkerson, Merck and the American Diabetes Association Challenge African Americans with Type 2 Diabetes to Get to Their A1C Goal PR Newswire
Jul-14-15 03:08PM  Johnson & Johnson edges Street views with weak 2Q
Jul-13-15 08:05AM  Short Sellers Run for Cover in Big Pharma at 24/7 Wall St.
Jul-09-15 05:24PM  FDA updates heart warnings on popular pain relievers
08:56AM  Barclays Expects M&A In Specialty Pharma To Continue, Likes Valeant And Jazz
Jul-08-15 04:40PM  Allergan Buys Rights to Merck's Migraine Drugs for $250M - Analyst Blog
08:59AM  Oppenheimer Says Sell These 9 Laggard S&P 500 Stocks at TheStreet
08:55AM  3 UBS Must-Own Large-Cap Pharmaceutical Stocks at 24/7 Wall St.
Jul-07-15 11:09PM  Business Watch: News Digest at The Wall Street Journal
Merck & Co., Inc. provides health care solutions worldwide. The company offer therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also offers neuromuscular blocking agents for use in surgery; anti-bacterial products for skin and skin structure infections; antidepressants; ophthalmic and cholesterol modification products; non-sedating antihistamine; and vaginal contraceptive implants. In addition, the company provides products to prevent chemotherapy-induced and post-operative nausea and vomiting; to treat brain tumors and melanoma; to prevent diseases caused by human papillomavirus, as well as vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers animal health products, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics for, and vaccines against bacterial and viral disease in fish. Additionally, the company provides companion animal products, such as diabetes mellitus treatment drugs and vaccines for dogs and cats; ointments for acute and chronic otitis; anthelmintic products; chewable tablets to kill fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. The company serves drug wholesalers and retailers, hospitals, government entities and agencies, physicians, physician distributors, veterinarians, distributors, and animal producers, as well as managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey. Merck & Co. Inc formerly operated as a subsidiary of Merck KGaA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schechter Adam HEVP & Pres-Global Human HealthMay 11Sale60.4410,634642,7680May 11 05:48 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyMay 08Option Exercise35.2846,2081,630,39670,353May 11 01:33 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyMay 08Sale60.9938,3682,339,94931,985May 11 01:33 PM
Kuhlik Bruce NExe V-P & Gen CounselMay 04Option Exercise39.2956,0642,202,755206,496May 05 04:46 PM
Kuhlik Bruce NExe V-P & Gen CounselMay 04Sale60.2056,0643,374,795150,432May 05 04:46 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyMay 02Option Exercise0.003,818025,359May 05 04:46 PM
Golestani ClarkEVP & Chief Info OfficerMay 02Option Exercise0.002,291010,259May 05 04:46 PM
GRADDICK WEIR MIRIAN MExe V-P, HRMay 02Option Exercise0.008,6540116,334May 05 04:46 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 02Option Exercise0.004,709015,129May 05 04:46 PM
Rosenblatt MichaelExec V-P & Chief Med OfficerMay 02Option Exercise0.003,818034,534May 05 04:46 PM
Schechter Adam HEVP & Pres-Global Human HealthMay 02Option Exercise0.0019,343019,343May 05 04:46 PM
Kuhlik Bruce NExe V-P & Gen CounselMay 02Option Exercise0.0011,7080156,503May 05 04:46 PM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerMay 02Option Exercise0.003,818020,794May 05 04:46 PM
Deese Willie AExe V-P & Pres. MMDMay 02Option Exercise0.007,6360122,631May 05 04:46 PM
DeLuca Richard R.EVP&Pres, Merck Animal HealthMay 02Option Exercise0.005,090014,564May 05 04:46 PM
Holston Michael JEVP, LegalApr 29Option Exercise44.39135,6246,020,460135,624Apr 29 06:01 PM
Kuhlik Bruce NExe V-P & Gen CounselApr 29Option Exercise38.51156,9026,042,441301,697Apr 29 06:01 PM
Holston Michael JEVP, LegalApr 29Sale59.8495,6245,722,54240,000Apr 29 06:01 PM
Kuhlik Bruce NExe V-P & Gen CounselApr 29Sale59.82156,9029,386,646144,795Apr 29 06:01 PM
HARRISON WILLIAM B JRDirectorApr 13Option Exercise33.835,000169,15011,400Apr 13 05:24 PM
FRAZIER KENNETH CChairman, President & CEOFeb 18Option Exercise31.847,082225,491358,564Feb 18 04:51 PM
FRAZIER KENNETH CChairman, President & CEOFeb 18Sale58.675,164302,959353,400Feb 18 04:51 PM
Deese Willie AExe V-P & Pres. MMDFeb 11Option Exercise40.44135,8645,494,524242,094Feb 11 02:19 PM
Deese Willie AExe V-P & Pres. MMDFeb 11Sale58.56135,8647,956,372106,230Feb 11 02:19 PM
WENDELL PETER CDirectorFeb 09Option Exercise33.835,000169,1506,000Feb 09 03:24 PM
WENDELL PETER CDirectorFeb 09Sale58.765,000293,7971,000Feb 09 03:24 PM
Schechter Adam HEVP & Pres-Global Human HealthJan 15Option Exercise41.1874,2003,055,57874,200Jan 15 03:55 PM
Schechter Adam HEVP & Pres-Global Human HealthJan 15Sale62.4874,2004,636,2240Jan 15 03:55 PM
FRAZIER KENNETH CChairman, President & CEOJan 09Option Exercise34.2012,874440,240360,322Jan 09 02:44 PM
FRAZIER KENNETH CChairman, President & CEOJan 09Sale62.478,840552,267351,482Jan 09 02:44 PM
FRAZIER KENNETH CChairman, President & CEODec 10Option Exercise34.2012,874440,240357,294Dec 10 05:59 PM
FRAZIER KENNETH CChairman, President & CEODec 10Sale60.009,846590,760347,448Dec 10 05:59 PM
Kuhlik Bruce NExe V-P & Gen CounselDec 08Option Exercise51.0250,0002,551,000178,467Dec 08 06:55 PM
Kuhlik Bruce NExe V-P & Gen CounselDec 08Sale62.0050,0003,100,000128,467Dec 08 06:55 PM
LAZARUS ROCHELLE BDirectorNov 26Option Exercise34.1410,000341,35014,595Nov 26 12:40 PM
LAZARUS ROCHELLE BDirectorNov 26Sale59.6310,000596,3004,595Nov 26 12:40 PM
WEEKS WENDELL PDirectorNov 24Option Exercise33.835,000169,1505,100Nov 25 07:08 PM
WEEKS WENDELL PDirectorNov 24Sale59.135,000295,663100Nov 25 07:08 PM
FRAZIER KENNETH CChairman, President & CEONov 10Option Exercise34.2012,875440,272354,420Nov 10 04:36 PM
FRAZIER KENNETH CChairman, President & CEONov 10Sale57.9810,000579,784344,420Nov 10 04:36 PM
DeLuca Richard R.EVP&Pres, Merck Animal HealthNov 02Option Exercise0.004,38704,387Nov 03 04:46 PM
FRAZIER KENNETH CChairman, President & CEOOct 10Option Exercise34.2012,875440,272351,440Oct 14 09:05 AM
FRAZIER KENNETH CChairman, President & CEOOct 10Sale59.739,895591,033341,545Oct 14 09:05 AM
FRAZIER KENNETH CChairman, President & CEOSep 10Option Exercise34.2012,875440,272348,379Sep 10 01:53 PM
FRAZIER KENNETH CChairman, President & CEOSep 10Sale60.489,814593,592338,565Sep 10 01:53 PM
FRAZIER KENNETH CChairman, President & CEOAug 11Option Exercise34.2012,875440,272345,562Aug 12 09:01 AM
FRAZIER KENNETH CChairman, President & CEOAug 11Sale57.0010,058573,306335,504Aug 12 09:01 AM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerAug 04Option Exercise45.3823,4001,061,82042,844Aug 05 09:56 AM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerAug 04Sale56.6428,6691,623,72014,175Aug 05 09:56 AM
REPRESAS CARLOS EDirectorAug 01Option Exercise35.195,000175,9505,500Aug 05 10:16 AM